Zymeworks Inc investor relations material

Zymeworks Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific, multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's proprietary Azymetric platform combines its modular and flexible Fc engineering with non-Fc-containing domains designed to enable modulation of therapeutic index in order to address multiple biological targets simultaneously from a single protein. The partnering team brings together a comprehensive set of skills and expertise spanning early drug discovery through product commercialization.